Literature DB >> 15982805

A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines.

Fang Zhao1, Jun Yan, Shengju Deng, Linxiang Lan, Fei He, Bin Kuang, Huihui Zeng.   

Abstract

Human thioredoxin reductase (TrxR) system is associated with cancer cell growth and anti-apoptosis process. Effects of 1, 2-[bis (1,2-Benzisoselenazolone-3 (2H) -ketone)]ethane (BBSKE), a novel TrxR inhibitor, were investigated on A549, HeLa, Bel-7402, BGC823 and KB cell lines. After treated with BBSKE, a good linear correlation coefficient (r>or=0.989) between TrxR activity and cell viability exists in each cell line together with cell growth/proliferation inhibition and apoptosis through Bcl-2/Bax and Caspase-3 pathways. These results suggest that there exists some relationship between TrxR inactivation and growth/proliferation inhibition or apoptosis in the investigated cell lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982805     DOI: 10.1016/j.canlet.2005.05.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

Review 1.  The cysteine proteome.

Authors:  Young-Mi Go; Joshua D Chandler; Dean P Jones
Journal:  Free Radic Biol Med       Date:  2015-04-03       Impact factor: 7.376

2.  Ethaselen: a novel organoselenium anticancer agent targeting thioredoxin reductase 1 reverses cisplatin resistance in drug-resistant K562 cells by inducing apoptosis.

Authors:  Suo-Fu Ye; Yong Yang; Lin Wu; Wei-Wei Ma; Hui-Hui Zeng
Journal:  J Zhejiang Univ Sci B       Date:  2017-05       Impact factor: 3.066

3.  Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest.

Authors:  Jia-Ning Fu; Jing Li; Qiang Tan; Han-Wei Yin; Kun Xiong; Tian-Yu Wang; Xiao-Yuan Ren; Hui-Hui Zeng
Journal:  Invest New Drugs       Date:  2010-03-02       Impact factor: 3.850

4.  Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model.

Authors:  Suo-Fu Ye; Jian Li; Shuang-Min Ji; Hui-Hui Zeng; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2016-12-05       Impact factor: 6.150

5.  Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.

Authors:  Qiang Tan; Jing Li; Han-wei Yin; Li-hui Wang; Wan-chen Tang; Fang Zhao; Xin-min Liu; Hui-hui Zeng
Journal:  Invest New Drugs       Date:  2009-03-07       Impact factor: 3.850

6.  Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer.

Authors:  Swaroop S Singh; Yun Li; Oscar Harris Ford; Carol S Wrzosek; Diana C Mehedint; Mark A Titus; James L Mohler
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

7.  A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells.

Authors:  Zuo-Fu Peng; Lin-Xiang Lan; Fang Zhao; Jing Li; Qiang Tan; Han-Wei Yin; Hui-Hui Zeng
Journal:  J Zhejiang Univ Sci B       Date:  2008-01       Impact factor: 3.066

8.  Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.

Authors:  Chaoran Liu; Zhong Liu; Meng Li; Xiaoling Li; Yum-Shing Wong; Sai-Ming Ngai; Wenjie Zheng; Yibo Zhang; Tianfeng Chen
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

9.  Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling.

Authors:  Ravinder Kodela; Niharika Nath; Mitali Chattopadhyay; Diandra E Nesbitt; Carlos A Velázquez-Martínez; Khosrow Kashfi
Journal:  Drug Des Devel Ther       Date:  2015-08-24       Impact factor: 4.162

10.  Differences in Redox Regulatory Systems in Human Lung and Liver Tumors Suggest Different Avenues for Therapy.

Authors:  Ryuta Tobe; Bradley A Carlson; Petra A Tsuji; Byeong Jae Lee; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Cancers (Basel)       Date:  2015-11-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.